Novo Nordisk’s Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and ...

Carolina Wealth Advisors, LLC added 102,629 shares of Novo Nordisk A/S, an estimated $6.01 million trade based on the average price for Q3 2025. The trade represented 2.6% of reportable AUM for the ...

NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, ...

(RTTNews) - Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, Inc., a publicly held clinicalstage company developing treatments for patients with serious metabolic ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. 10 ...

Novo Nordisk has a significant presence in the U.S. manufacturing sector and is expanding its facility. The administration won't impose tariffs until negotiations are closed. The drugmaker is awaiting ...

CHICAGO (Reuters) -A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government’s program that gives its Medicare health insurance plan the power to negotiate lower drug ...

Monday's downgrading entity was white-shoe investment bank Morgan Stanley, whose analyst Thibault Boutherin felt compelled to rerate Novo Nordisk as an underweight (sell, in other words). Previously, ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...